论文部分内容阅读
目的:从日本PCT申请中寻找心血管疾病治疗药物研发的思路。方法:对申请日从2005年1月1日至2014年12月31日的日本心血管系统疾病治疗药物PCT申请进入中国国家阶段后失效的专利申请及专利数据进行整序和分析,依据其在日本本土的法律状态确定其技术含金量。结果:未得到中国专利保护的日本心血管系统疾病治疗药物PCT申请共167件。结论:167件日本心血管系统疾病治疗药物PCT申请进入日本国家阶段后,107件申请在日本本土未得到保护,2件需继续跟踪在日本的法律状态,其所含信息量应该相当于公开发表的论文的信息量,58件在日本本土授权的专利技术具有一定的技术含金量,目前在中国已经进入公知公用领域,经过自由实施检索和专利尽职检索后可以无偿使用。
OBJECTIVE: To find a way to research and develop cardiovascular medicine from Japanese PCT application. Methods: The patent application and patent data that failed after the PCT application for the treatment of cardiovascular disease in Japan that applied on the filing date from January 1, 2005 to December 31, 2014, entered China’s national phase were collated and analyzed according to The legal status of Japan determines its technical gold content. Results: There were 167 PCT applications for the treatment of cardiovascular diseases in Japan that were not protected by Chinese patents. CONCLUSIONS: Of the 167 Japanese medicines used to treat cardiovascular diseases, 107 were not protected in Japan after the PCT application entered Japan’s national phase, and 2 were required to keep track of the legal status in Japan and should contain as much information as publicly available Of the amount of information on the paper, 58 pieces of proprietary technology licensed in Japan has a certain amount of technical gold, has now entered the public domain in China, after free search and patent due diligence search can be used for free.